April 2022 Issue Table Of Contents

From The Editor

• Who Are The “Right” People?

Feature Articles

• Thinking Differently About Rare Disease Therapies

CEO Corner

• An Intentionally Unconventional Journey To CEO

Companies To Watch

• Global Blood Therapeutics

Industry Research

• Drug Product CDMO Selection Metrics Point Toward Pandemic-Induced Concern

Industry Leader

• Achieving True Patient Centricity Means Shaping The Long-Term Culture Of Change
• Building The Medical Supply Chain’s Immunity To Disruption
• You Are a New CEO … Now What?
• Workplace Etiquette:  22 Do’s For 2022

Inside The Industry

• 7 Strategies To Improve Clinical Trial Success
• How To Advance A Bold Vision In The Face Of Ambiguity
• Beyond Profits To Biopharma Innovation
• 3 Essentials For A Fit-For-Purpose Compliance Strategy In Decentralized Pharma
• Outsourcers Are Feeling Uneasy About Continuity of Supply and It Is Influencing CDMO
• Platforms To Pipelines: Part 1
• A Q&A With A Venture Capitalist/Genetic Medicines Executive
• The Life Sciences Supply Chain Resilience Framework
• What’s It Like Being A Termeer Fellow?

Leadership Lessons

• Why Discomfort Is Necessary For Continued Expansion
• Can The British Monarchy Teach Modern Pharma Leaders A Lesson?

Ask The Board

• What Have Been The Most Valuable Lessons Learned Over The Past Two Years?
• What Technologies Do You Anticipate Disrupting Vaccine Manufacturing And Why?
• What Would You Say To An Executive Who States They Don’t Know How To Manage/Lead Millennials?